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Gleason score has been identified as an important pre-
dictor of disease extent and the biologic behavior of
prostate cancer. Despite statistically significant agree-
ment between biopsy and prostatectomy Gleason
scores, under-grading remains a major problem in
clinical practice. Histologic grades, based on biopsy
specimens, predict grades from corresponding pros-
tatectomy specimens in most (72–83%), but not all,
cases.1 In this issue of the journal, Hsieh et al provide
a well-written article, with a clear answer regarding
the role of prostate biopsy in final prostate-cancer
grading.2
Potential reasons for discordance between Gleason
scores obtained from prostate biopsy and those ob-
tained from surgical specimens are pathologic inter-
pretation bias and sampling effects.3,4 Besides the low
detection rate of focal lesions by transrectal ultraso-
nography, the limitations of biopsy sample size and
sampling bias make differences in grading between
biopsy and radical prostatectomy specimens unavoid-
able. Well-differentiated tumors detected by biopsy
sample are not predictive of organ-confined disease,
but a poorly differentiated lesion is a good indica-
tor of extracapsular extension of cancer. Treatment
algorithms for particularly well-differentiated tu-
mors should not be deduced from biopsy histology
alone. The prediction of prostatectomy Gleason score
is only marginally improved by increasing the number
of biopsies, and a unilateral positive biopsy does not
predict unilateral disease. High values for prostate-
specific antigen (PSA) at diagnosis, Gleason score, and
the percentage of positive biopsies, are important
predictors of under-staging.5 The percentage of positive
biopsies should be incorporated into risk-assessment
models for newly diagnosed prostate cancer.
Prostate biopsy should be repeated when an initial
diagnosis of adenocarcinoma is based only on limited
amounts of neoplastic tissue with a low Gleason
score, and management decisions should be influenced
only by the true Gleason score of the tumor.6 Thus,
additional parameters, such as PSA level and tumor
volume, should be considered together with cellular
differentiation, in the decision-making process for
the management of newly diagnosed patients with
prostate cancer.
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